Pfizer (PFE) Stock Forecast & Price Target

$25.76 -0.41 (-1.57%)

(As of 11/26/2024 ET)

Pfizer - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 16 Analyst Ratings

Sell
1

Hold
8

Buy
7

Based on 16 Wall Street analysts who have issued ratings for Pfizer in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 1 has given a sell rating, 8 have given a hold rating, 5 have given a buy rating, and 2 have given a strong buy rating for PFE.

Consensus Price Target

$32.92
27.81% Upside

According to the 16 analysts' twelve-month price targets for Pfizer, the average price target is $32.92. The highest price target for PFE is $45.00, while the lowest price target for PFE is $25.00. The average price target represents a forecasted upside of 27.81% from the current price of $25.76.

Get the Latest News and Ratings for PFE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Pfizer and its competitors.

PFE Analyst Ratings Over Time

Type	Current Forecast 11/28/23 to 11/27/24	1 Month Ago 10/29/23 to 10/28/24	3 Months Ago 8/30/23 to 8/29/24	1 Year Ago 11/28/22 to 11/28/23
Strong Buy	2 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	5 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)
Hold	8 Hold rating(s)	8 Hold rating(s)	8 Hold rating(s)	11 Hold rating(s)
Sell	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$32.92	$33.58	$34.54	$42.50
Forecasted Upside	27.81% Upside	16.33% Upside	20.30% Upside	43.15% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold

Top secret Trump trades? (Ad)

As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”

Go here to see how you can start accessing these opportunities today

PFE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

PFE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Pfizer Stock vs. The Competition

Type	Pfizer	Medical Companies	S&P 500
Consensus Rating Score	2.50	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	27.81% Upside	25,264.18% Upside	6.73% Upside
News Sentiment Rating	Positive News See Recent PFE News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/15/2024	Wolfe Research 3 of 5 stars	A. Hammond Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underperform	$25.00	-3.92%
10/30/2024	Evercore ISI 2 of 5 stars	U. Raffat Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
10/25/2024	Citigroup 3 of 5 stars		Initiated Coverage	Neutral	$30.00	+4.71%
10/23/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$45.00 ➝ $45.00	+55.93%
10/17/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Breen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$32.00	+7.89%
8/7/2024	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	N. Nakagiri Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy ➝ Strong-Buy
Get the Latest News and Ratings for PFE and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Pfizer and its competitors with MarketBeat's FREE daily newsletter.
8/7/2024	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Outperform	$28.00 ➝ $34.00	+14.21%
7/31/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$30.00 ➝ $32.00	+4.51%
7/31/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$28.00 ➝ $30.00	-3.23%
7/31/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$30.00 ➝ $31.00	+0.23%
5/2/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$28.00 ➝ $29.00	+4.28%
5/2/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$33.00 ➝ $36.00	+30.62%
3/22/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
2/23/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$36.00	+30.67%
1/4/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform	$32.00	+7.67%
12/14/2023	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$42.00 ➝ $36.00	+37.35%
10/16/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$36.00 ➝ $34.00	+0.71%
10/16/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$38.00 ➝ $39.00	+21.46%
7/14/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$50.00	+38.66%
6/29/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Neutral	$47.00 ➝ $40.00	+10.22%
4/21/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral	$50.00 ➝ $45.00	+12.92%
2/7/2023	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Kerry Holford Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target		$40.00	-8.24%
2/1/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Market Perform	$49.00 ➝ $48.00	+8.70%
2/1/2023	Atlantic Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral	$50.00 ➝ $46.00	+4.17%
12/13/2022	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Chris Shibutani Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$47.00 ➝ $60.00	+15.03%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 07:21 AM ET.

Should I Buy Pfizer Stock? PFE Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, November 22, 2024. Please send any questions or comments about these Pfizer pros and cons to contact@marketbeat.com.

Pfizer
Bull Case

Here are some ways that investors could benefit from investing in Pfizer Inc.:

Pfizer Inc. reported a strong quarterly earnings result with earnings per share (EPS) of $1.06, significantly exceeding analysts' expectations of $0.64. This indicates robust financial performance and potential for future growth.
The company achieved a revenue of $17.70 billion for the quarter, which is a 31.2% increase year-over-year, showcasing its ability to grow sales effectively.
Pfizer Inc. has a current stock price of $25.06, which is near its 12-month low of $24.48, potentially offering a buying opportunity for investors looking for value.
Analysts have a "Moderate Buy" average rating for Pfizer Inc., with a target price of $32.92, suggesting that there is room for price appreciation in the stock.
The company has a solid dividend yield of 6.77%, providing investors with a steady income stream, which is particularly attractive in a low-interest-rate environment.

Pfizer
Bear Case

Investors should be bearish about investing in Pfizer Inc. for these reasons:

Despite recent earnings growth, Pfizer Inc. has a high payout ratio of 227.03%, indicating that it pays out more in dividends than it earns, which could be unsustainable in the long run.
The stock has experienced volatility, with a beta of 0.67, suggesting that it may not be as stable as some investors prefer, especially in uncertain market conditions.
There is a mixed outlook from analysts, with one sell rating and several hold ratings, indicating that not all market participants are confident in the stock's future performance.
Institutional ownership is significant at 68.36%, which can lead to increased volatility if large investors decide to sell their positions.
Recent insider activity shows that while some directors are buying shares, the overall insider ownership is only 0.06%, which may indicate a lack of confidence from those closest to the company.

PFE Forecast - Frequently Asked Questions

: According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Pfizer is $32.92, with a high forecast of $45.00 and a low forecast of $25.00.
: 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There is currently 1 sell rating, 8 hold ratings, 5 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PFE shares.
: According to analysts, Pfizer's stock has a predicted upside of 27.81% based on their 12-month stock forecasts.
: Over the previous 90 days, Pfizer's stock had 1 upgrade by analysts.
: Pfizer has been rated by research analysts at Cantor Fitzgerald, Citigroup, Evercore ISI, Sanford C. Bernstein, and Wolfe Research in the past 90 days.
: Analysts like Pfizer less than other "medical" companies. The consensus rating score for Pfizer is 2.50 while the average consensus rating score for "medical" companies is 2.80. Learn more on how PFE compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

This Bull Market Indicator called NVDA at $116 (Ad)

Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…

All you have to do is follow this link here

This page (NYSE:PFE) was last updated on 11/27/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pfizer (PFE) Stock Forecast & Price Target